Literature DB >> 23873881

Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation).

Ana García-Martínez1, Pedro Arguis2, Sergio Prieto-González3, Georgina Espígol-Frigolé3, Marco A Alba3, Montserrat Butjosa1, Itziar Tavera-Bahillo1, José Hernández-Rodríguez3, Maria C Cid3.   

Abstract

BACKGROUND: Aortic structural damage (ASD) may complicate the course of patients with giant cell arteritis (GCA). However the frequency and outcome of ASD has not been assessed in long term prospective studies.
METHODS: In a previous screening of 54 biopsy proven GCA patients, significant ASD was detected in 12 (22.2%) after a median follow-up of 5.4 years. These patients were periodically evaluated (every 4 years) over a median of 10.3 years (range 4-16.6 years) in order to investigate the development of new ASD and the outcome of previously detected abnormalities.
RESULTS: 18 of the 54 patients abandoned the study due to death or other reasons. The remaining 36 patients were subjected to a second screening and 14 to a third screening. 12 (33.3%) of the 36 patients re-screened and 16 (29.6%) of the initial cohort developed ASD, all but one in the thoracic aorta. Aortic diameters at the ascending and descending aorta significantly increased over time. One patient (1.9% of the initial cohort) died from aortic dissection. Surgery was advised in eight (50%) patients with ASD but could only be performed in three patients (37.7%). The development of ASD was not associated with persistence of detectable disease activity.
CONCLUSIONS: The incidence of ASD is maximal within the first 5 years after diagnosis but continues developing over time, affecting up to 33.3% of individuals after long term follow-up. Once ASD occurs, dilatation increases over time, underlining the need for periodic evaluation. Surgical repair is feasible in about one-third of candidates. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Cardiovascular Disease; Corticosteroids; Giant Cell Arteritis; Outcomes research; Systemic vasculitis

Mesh:

Year:  2013        PMID: 23873881     DOI: 10.1136/annrheumdis-2013-203322

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Arterial lesions in giant cell arteritis: A longitudinal study.

Authors:  Tanaz A Kermani; Sehriban Diab; Antoine G Sreih; David Cuthbertson; Renée Borchin; Simon Carette; Lindsy Forbess; Curry L Koening; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Robert F Spiera; Kenneth J Warrington; Steven R Ytterberg; Carol A Langford; Peter A Merkel; Nader A Khalidi
Journal:  Semin Arthritis Rheum       Date:  2018-05-09       Impact factor: 5.532

Review 2.  Giant cell arteritis: Current treatment and management.

Authors:  Cristina Ponte; Ana Filipa Rodrigues; Lorraine O'Neill; Raashid Ahmed Luqmani
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

3.  Fever of unknown origin, giant cell arteritis, and aortic dissection.

Authors:  K Hofheinz; S Bertz; J Wacker; G Schett; B Manger
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

Review 4.  Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.

Authors:  Soumya Chatterjee; Scott D Flamm; Carmela D Tan; E Rene Rodriguez
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

5.  Vasculitis syndromes: Tocilizumab - a new frontier for GCA therapy.

Authors:  Matthew J Koster; Kenneth J Warrington
Journal:  Nat Rev Rheumatol       Date:  2017-09-07       Impact factor: 20.543

Review 6.  EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice summary.

Authors:  Mohammad Bardi; Andreas P Diamantopoulos
Journal:  Radiol Med       Date:  2019-06-28       Impact factor: 3.469

7.  Magnetic resonance imaging-based diagnosis of aortitis preceding development of a thoracic aneurysm in a patient with giant cell arteritis: a case report.

Authors:  Georg Lutter; Thomas Puehler; Christoph Röcken; Marcus Both
Journal:  Eur Heart J Case Rep       Date:  2022-04-12

Review 8.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

9.  CT analysis of the aorta in giant-cell arteritis: a case-control study.

Authors:  Pierre Emmanuel Berthod; Serge Aho-Glélé; Paul Ornetti; Olivier Chevallier; Hervé Devilliers; Frédéric Ricolfi; Bernard Bonnotte; Romaric Loffroy; Maxime Samson
Journal:  Eur Radiol       Date:  2018-03-29       Impact factor: 5.315

10.  Boundaries of a systemic disease: a protean presentation of giant cell arteritis.

Authors:  António Mesquita; Lara Camara; Catarina Patrício; Vítor Brotas
Journal:  BMJ Case Rep       Date:  2020-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.